Innovent Biologics and Takeda have announced a sweeping $11.4 billion oncology alliance focused on global co-development and commercialization of immuno-oncology and ADC drug candidates.

Cambrex announces a major $120 million investment to expand active pharmaceutical ingredient (API) manufacturing capacity in the U.S., targeting enhanced supply chain resilience.

EVOQ Therapeutics has entered into a Collaboration and Licence Agreement with Sanofi. The partnership focuses on advancing EVOQ’s proprietary NanoDisc technology, which aims to restore the body’s natural immune tolerance mechanisms. 

Minovia Therapeutics Ltd. a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline

Celltrion has received approval from the U.S. Food and Drug Administration (FDA) for EYDENZELT® (aflibercept-boav), a biosimilar referencing EYLEA® (aflibercept). 

Vivace Therapeutics, Inc., a biotechnology company focused on developing small molecule cancer therapies that target the Hippo pathway, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA)

Made Scientific, a leading clinical and commercial-enabling cell therapy contract development and manufacturing organization (CDMO), and Streamline Bio, a next-generation autonomous robotics company solving critical challenges

AbbVie today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois.

Cellectar Biosciences, Inc. a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist Contract Research Organization (CRO), have entered into an agreement whereby

Merck, a leading science and technology company, and Siemens, a leading technology company, signed a new Memorandum of Understanding (MoU), extending their strategic partnership to accelerate digital transformation in the life science industry